Zambon SpA is engaged in manufacturing pharmaceutical products. It offers anauran, anaurette, asacol, codex, fluimucil, and giason. The company is headquartered in Bresso, Italy.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Lactiga, Inc. operates as bio Therapeutics Company, which develops biologic to prevent mucosal infections. Its product, LCTG-001, is designed for patients with Primary Immunodeficiency Diseases (PID), including Selective IgA Deficiency (SIgAD) and Common Variable Immunodeficiency (CVID). The company was founded by Viraj Mane and Rikin Mehta and is headquartered in Toronto, Canada.

The Howard Hughes Medical Institute is a non-profit medical research organization that aims to advance biomedical research and science education. It seeks to strengthen education in biology and related sciences from elementary school to graduate studies by introducing science education programs. The institute’s offerings include BioInteractive: free resources for science teachers and students, including animations, short films, and apps; HHMI Bulletin: a science magazine that explores biomedical research through in-depth features, news, and perspectives; Janelia Research Campus: a research center where scientists pursue challenging problems in a collaborative setting; and Tangled Bank Studios: a production company that creates science films for broadcast, cinema, and digital media. The Howard Hughes Medical Institute was founded by Howard Hughes in 1953 and is based in Chevy Chase, Maryland.

CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.

Part of British American Tobacco plc, British American Tobacco (Germany) GmbH is a German company located in Hamburg that provides tobacco related products. Ralf Wittenberg is the current CEO of the firm.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.

Anergen is a brand of hypoallergenic cat and dog food manufactured by Wysong.

Youlikang (Jiangsu) Biopharmaceutical Co., Ltd., established on 2015-04-10, Business scope includes licensed projects:pharmaceutical production;food production;Production of Class II Medical Devices;Cosmetic production;food sales;Health food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Food import and export;Import and export;Technical extension services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;production of agricultural products,Sales,processing,transportation,Storage and other related services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)